Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixmyelocel-T in Critical Limb Ischemia
NCT00468000Phase 2Completed
- Sponsor
- Vericel
- Start
- Apr 2007
- Primary completion
- Mar 2011
- Modality
- Mesenchymal Stem Cells, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in critical limb ischemia (CLI) comparing Ixmyelocel-T with Placebo (2 arms). Primary endpoint: Safety of TRCs in patients with CLI. Started Apr 2007; status: completed.
02
Drugs
ixmyelocel-T
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT00468000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00468000.